Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy.

Hoang T, Schiller JH.

Expert Rev Anticancer Ther. 2002 Aug;2(4):393-401. Review.

PMID:
12647982
2.

Current management of advanced non-small cell lung cancer: targeted therapy.

Isobe T, Herbst RS, Onn A.

Semin Oncol. 2005 Jun;32(3):315-28. Review.

PMID:
15988686
3.

Novel targeted agents in the treatment of lung cancer.

Saba N, Khuri F.

Expert Opin Investig Drugs. 2004 Jun;13(6):609-29. Review.

PMID:
15174948
4.

Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.

Gridelli C, Massarelli E, Maione P, Rossi A, Herbst RS, Onn A, Ciardiello F.

Cancer. 2004 Oct 15;101(8):1733-44. Review.

5.

Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer.

Gridelli C, Maione P, Airoma G, Rossi A.

Curr Med Chem. 2002 Nov;9(21):1851-8. Review.

PMID:
12369871
6.

The role of new agents in the treatment of non-small cell lung cancer.

Bröker LE, Giaccone G.

Eur J Cancer. 2002 Dec;38(18):2347-61. Review.

PMID:
12460778
7.

Novel therapies for the treatment of non-small cell lung cancer.

Johnson DH, Schiller JH.

Cancer Chemother Biol Response Modif. 2002;20:763-86. Review.

PMID:
12703233
8.

[Cyclooxygenase 2 inhibitors and lung carcinoma].

Spano JP, Chouahnia K, Morère JF.

Bull Cancer. 2004 May;91 Spec No:S109-12. Review. French.

PMID:
15239338
9.

New targets for the treatment of advanced non-small cell lung cancer.

Massarelli E, Onn A, Zinner R, Khuri FR, Kim ES, Herbst RS.

Cancer Chemother Biol Response Modif. 2002;20:717-61. Review. No abstract available.

PMID:
12703232
10.

Novel approaches to the treatment of non-small cell lung cancer.

Ferreira CG, Huisman C, Giaccone G.

Crit Rev Oncol Hematol. 2002 Jan;41(1):57-77. Review.

PMID:
11796232
11.

New chemotherapeutic agents: update of major chemoradiation trials in solid tumors.

Curran WJ.

Oncology. 2002;63 Suppl 2:29-38. Review.

PMID:
12466642
12.

COX-2 inhibition and lung cancer.

Sandler AB, Dubinett SM.

Semin Oncol. 2004 Apr;31(2 Suppl 7):45-52. Review.

PMID:
15179623
13.

[New therapies for non-small cell lung cancer].

Ostoros G, Kovács G, Szondy K, Döme B.

Orv Hetil. 2005 May 22;146(21):1135-41. Review. Hungarian.

PMID:
15991677
14.

Novel therapies for lung cancer.

Hoang T, Traynor AM, Schiller JH.

Surg Oncol. 2002 Dec;11(4):229-41. Review.

PMID:
12450559
15.

Targeted therapies: focus on a new strategy for gastrointestinal tumors.

Nicolella D, Maione P, Gridelli C.

Crit Rev Oncol Hematol. 2003 Sep;47(3):261-71. Review.

PMID:
12962900
16.

[Cyclooxygenase 2 inhibitors and lung carcinoma].

Spano JP, Chouahnia K, Morère JF.

Bull Cancer. 2004 May;91 Suppl 2:S109-12. Review. French.

17.

Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.

Vokes EE, Choy H.

Lung Cancer. 2003 Aug;41 Suppl 1:S115-21. Review.

PMID:
12867070
18.

Clinical impact of novel treatment strategies.

Giaccone G.

Oncogene. 2002 Oct 7;21(45):6970-81. Review.

19.

Systemic therapy for advanced pancreatic cancer.

El-Rayes BF, Philip PA.

Expert Rev Anticancer Ther. 2002 Aug;2(4):426-36. Review.

PMID:
12647986
20.

Cyclooxygenase as a target in lung cancer.

Brown JR, DuBois RN.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4266s-4269s. Review.

Supplemental Content

Support Center